Can a blood test and special scan spot breast cancer relapse before symptoms?

NCT ID NCT06225505

Recruiting now Knowledge-focused Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study looks at whether regular blood tests (ctDNA monitoring) combined with a special type of PET scan can detect the return of triple negative breast cancer earlier than standard methods. About 450 women who finished treatment for early-stage triple negative breast cancer will take part. If the blood test shows signs of cancer, some participants will get the special scan to see if it helps find relapses sooner.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

CHU Nîmes
NOT_YET_RECRUITING

Nîmes, 30900, France
Centre Eugène Marquis
NOT_YET_RECRUITING

Rennes, 35000, France
Centre Jean Perrin
NOT_YET_RECRUITING

Clermont-Ferrand, 63011, France
Centre Leon Bérard
NOT_YET_RECRUITING

Lyon, 69008, France
Hôpital Saint-Louis
NOT_YET_RECRUITING

Paris, 75010, France
Hôpital Tenon
NOT_YET_RECRUITING

Paris, 75020, France
Institut Bergonié
NOT_YET_RECRUITING

Bordeaux, 33000, France
Institut Curie
RECRUITING

Saint-Cloud, 92340, France
Institut Paoli-Calmettes
NOT_YET_RECRUITING

Marseille, 13009, France
Institut de cancérologie de Lorraine
NOT_YET_RECRUITING

Vandœuvre-lès-Nancy, 54519, France
Institut du cancer de Montpellier
NOT_YET_RECRUITING

Montpellier, 34298, France
ONCOPOLE Claudius Regaud
NOT_YET_RECRUITING

Toulouse, 31059, France
Sainte-Catherine Institut du Cancer Avignon-Provence
NOT_YET_RECRUITING

Avignon, 84918, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.